{"schema_version":"1.0","type":"article","title":"不賣給大藥廠，4 家生技公司憑什麼自己做大？","url":"https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling.md","lang":"zh-Hant","date":"2026-08-08","publish_at":"2026-08-08T08:00:00+08:00","updated_at":"2026-08-08","category":"商業分析系列","topic":"商業分析系列","tags":["Biotech","Biopharma","argenx","Insmed","Revolution Medicines","Incyte","Royalty Pharma","新藥開發","生技投資"],"summary":"argenx、Insmed、Incyte 與 Revolution Medicines 選擇保留獨立經營權。真正的不賣資格，來自產品證據、現金引擎、第二曲線、全球執行與不交出控制權也能取得資金的能力。","key_points":[],"facts":[],"sections":["第一關｜一款藥能不能從產品，變成資本引擎？","第二關｜第二款藥，驗收組織能不能複製成功","Incyte 的提醒｜會賺錢，市場為何還不買單？","Revolution｜賣掉一部分未來，換回控制權","想說「不賣」，先過這五關","台灣生技更該學會替自己保留選擇權","結論｜被收購能兌現，獨立要能重複成功","參考資料","免責聲明"],"references":[{"title":"以下均為公司、SEC 或主管機關一級來源；查證截止：2026-08-07。","source":"","date":"","url":""},{"title":"[argenx FY2025 財務結果]","source":"","date":"","url":"https://argenx.com/news/2026/press-release-3245199"},{"title":"[argenx 2026 H1／Q2 財務結果]","source":"","date":"","url":"https://argenx.com/news/2026/press-release-3331862.html"},{"title":"[Insmed FY2025 財務結果]","source":"","date":"","url":"https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update"},{"title":"[Insmed 2026 Q2 財務結果]","source":"","date":"","url":"https://investor.insmed.com/2026-08-06-Insmed-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update"},{"title":"[Insmed SEC filings]","source":"","date":"","url":"https://investor.insmed.com/financial-information/sec-filings"},{"title":"[Incyte FY2025 財務結果]","source":"","date":"","url":"https://investor.incyte.com/news-releases/news-release-details/incyte-reports-fourth-quarter-and-full-year-2025-financial"},{"title":"[Incyte 2025 Form 10-K]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm"},{"title":"[Incyte 2026 Q1 財務結果]","source":"","date":"","url":"https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides"},{"title":"[Revolution Medicines RASolute 302 第三期結果]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-asco-plenary-presentation"},{"title":"[Revolution Medicines EMA phased review 公告]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/european-medicines-agency-expedites-assessment-revolution"},{"title":"[FDA 接受 daraxonrasib NDA 審查公告]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-new-drug-application-daraxonrasib-accepted/"},{"title":"[Revolution Medicines 2026 Q1 財務結果]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-first-quarter-2026-financial/"},{"title":"[Revolution Medicines 2026 Q1 Form 10-Q]","source":"","date":"","url":"https://ir.revmed.com/static-files/e7a99744-380a-4fa9-93b6-2fb71793c8ee"},{"title":"[Revolution Medicines 2026 年 4 月融資 8-K]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526159289/d95226d8k.htm"},{"title":"[Royalty Pharma 與 Revolution Medicines 融資協議]","source":"","date":"","url":"https://www.royaltypharma.com/news/royalty-pharma-and-revolution-medicines-enter-into-funding-agreements-for-up-to-2-billion/"},{"title":"[Royalty Pharma 2026-04-13 8-K]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/d871473d8k.htm"}],"images":[{"alt":"不賣給大藥廠的五個條件：產品證據、現金引擎、第二曲線、全球執行與融資選項","url":"https://drugnews.com.tw/assets/articles/biotech-independence-not-selling/figure-01.png"},{"alt":"四家公司走在不同的獨立經營階段","url":"https://drugnews.com.tw/assets/articles/biotech-independence-not-selling/figure-02.png"},{"alt":"Revolution Medicines 以融資保留控制權，同時承擔 15 年權利金與債務成本","url":"https://drugnews.com.tw/assets/articles/biotech-independence-not-selling/figure-03.png"},{"alt":"判斷 Biotech 是否有不賣資格的五個問題","url":"https://drugnews.com.tw/assets/articles/biotech-independence-not-selling/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/biotech-independence-not-selling/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-08）。不賣給大藥廠，4 家生技公司憑什麼自己做大？。https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-08-biotech-independence-not-selling-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}